“The lines are fallen unto me in pleasant places; yea, I have a goodly heritage. I will bless the Lord, who hath given me counsel...” Psalms 16:6-7.. I matched into neurosurgery at the Mass General Hospital!!
#WashUMed
#Match2020
. Thanks to my family, friends,
@WashUNeurosurg
Today, 3 first release papers published in Science, including our review article continue to elucidate TIR enzyme function. Thankful for this contribution! Cheers to PGY3!
@WashUGenetics
@WUSTLmstp
@MGHNeurosurg
@HHMINEWS
“When you are with family, you are yourself. And when you are yourself, you are at your very best.” Mike Krzyzewski. The new members of my family. Nathan Sisterson, Bobby Gramer
@MGHNeurosurg
.
Very thankful for this opportunity, trust, and huge investment by the HHMI. In the words of a dept chairman, “We’re going to use every available technology, method, and procedure to improve the lives of patients all over the world.”
@MGHNeurosurg
@ChrisAWalsh1
@BostonChildrens
🎉 Today we're thrilled to announce our 2023
#HannaGrayFellows
! Please join us in welcoming and celebrating these outstanding early career scientists!
Learn more:
In 2017, we reported SARM1 as the founding member of a new family of enzymes. New work from others shares insights on how this neuronal enzyme is turned on and activated. Hoping to study the role of SARM1 in neurosurgical conditions.
Excellent work from the Walsh and Park labs published today highlighting the rates and patterns of somatic mutations in single neurons and oligodendrocytes during aging, w/ implications for age related brain conditions including brain tumors.
@CellCellPress
@ChrisAWalsh1
Today we’re announcing an agreement to acquire biotech company Disarm Therapeutics, expanding our R&D efforts in pain and neurodegeneration. Learn more:
Amazing program for early career scientists! Encouraging all my fellow post-docs, physician-scientists, surgeon-scientists that are eligible to apply!
#HannaGrayFellows
Applications for the 2024
#HannaGrayFellows
Program are now open!
At HHMI, we believe in 'People, not projects.' Join the Hanna Gray Fellows Program and be part of a community where every scientist's journey and contribution matters.
Media moves fast — but an effective data + AI platform moves faster✨
@CondeNast
uses Unity Catalog and Databricks SQL to speed up their analytics + decision-making and keep up with ever-changing trends, all while reducing infrastructure costs by $6M ⬇️
When we found that the TIR domain of neuronal SARM1 was an NADase, we had something special. We quickly defined this new enzyme family in bacteria and plants. Great to see TIR NADase play a role in prokaryotic STING biology. The beauty of basic research. From nerves to bacteria!
A study in Nature reports the discovery of prokaryotic STING and shows that the mechanism of activation is conserved between prokaryotes and eukaryotes.
Today, we place
#TIR
domains,
#NAD
, and
#SARM1
on the public map again. The TIR domain is indeed an emerging family of NAD consuming enzymes. We and others publish back to back papers in Science today. Enjoy! Check our Horsefield et al in the same issue.
Two-part article published in November issue of
@TheJNS
. On using peripheral
#nerve
surgery to reanimate paralyzed upper extremity muscles after cervical spinal cord injury.
#SCI
@WashUNeurosurg
Part 1:
Part 2:
The choroid plexus blood-CSF barrier has remained a mystery for far too long! Our study led by
@NeilCDani1
and Rebecca Herbst, w/ Aviv Regev &
@naomi_habib
, is out today in
@CellCellPress
showcasing a cell atlas & exciting new findings. 1/11
Read it here
SARM1 is the founding member of a new family of enzymes. Efforts are underway to block neurodegeneration via SARM1 inhibition. Thankful to have made the seminal discovery of Toll/Interleukin-1 Receptor (TIR) domain enzymes.